It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Examination of early phases of synucleinopathy when inclusions are present, but long before neurodegeneration occurs, is critical to both understanding disease progression and the development of disease modifying therapies. The rat alpha-synuclein (α-syn) preformed fibril (PFF) model induces synchronized synucleinopathy that recapitulates the pathological features of Parkinson’s disease (PD) and can be used to study synucleinopathy progression. In this model, phosphorylated α-syn (pSyn) inclusion-containing neurons and reactive microglia (major histocompatibility complex-II immunoreactive) peak in the substantia nigra pars compacta (SNpc) months before appreciable neurodegeneration. However, it remains unclear which specific genes are driving these phenotypic changes. To identify transcriptional changes associated with early synucleinopathy, we used laser capture microdissection of the SNpc paired with RNA sequencing (RNASeq). Precision collection of the SNpc allowed for the assessment of differential transcript expression in the nigral dopamine neurons and proximal glia. Transcripts upregulated in early synucleinopathy were mainly associated with an immune response, whereas transcripts downregulated were associated with neurotransmission and the dopamine pathway. A subset of 29 transcripts associated with neurotransmission/vesicular release and the dopamine pathway were verified in a separate cohort of males and females to confirm reproducibility. Within this subset, fluorescent in situ hybridization (FISH) was used to localize decreases in the Syt1 and Slc6a3 transcripts to pSyn inclusion-containing neurons. Identification of transcriptional changes in early synucleinopathy provides insight into the molecular mechanisms driving neurodegeneration.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Michigan State University, Department of Translational Science and Molecular Medicine, Grand Rapids, USA (GRID:grid.17088.36) (ISNI:0000 0001 2195 6501); Michigan State University, Neuroscience Program, East Lansing, USA (GRID:grid.17088.36) (ISNI:0000 0001 2195 6501)
2 Michigan State University, Department of Translational Science and Molecular Medicine, Grand Rapids, USA (GRID:grid.17088.36) (ISNI:0000 0001 2195 6501)
3 Michigan State University, Department of Translational Science and Molecular Medicine, Grand Rapids, USA (GRID:grid.17088.36) (ISNI:0000 0001 2195 6501); Michigan State University, Department of Pharmacology and Toxicology, East Lansing, USA (GRID:grid.17088.36) (ISNI:0000 0001 2195 6501)
4 Michigan State University, Department of Translational Science and Molecular Medicine, Grand Rapids, USA (GRID:grid.17088.36) (ISNI:0000 0001 2195 6501); Rutgers University, Department of Pharmacology and Toxicology, Piscataway, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796); Rutgers University, Environmental and Occupational Health Science Institute, Piscataway, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796)
5 University of Pennsylvania Perelman School of Medicine, Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)